Rocket Pharmaceuticals Q3 net loss narrows

Reuters11-07

Rocket Pharmaceuticals Q3 net loss narrows

Overview

Rocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior year
R&D and G&A expenses decreased due to disciplined resource allocation
Company to resume pivotal Phase 2 trial for Danon disease in 1H 2026

Outlook

Rocket expects cash resources to fund operations into Q2 2027
Company anticipates dosing additional patients for RP-A501 in H1 2026
KRESLADI™ PDUFA date set for March 28, 2026

Result Drivers

AAV CARDIOVASCULAR FOCUS - Co maintained strategic focus on AAV cardiovascular gene therapy portfolio, resuming pivotal Phase 2 trial for Danon disease
EXPENSE REDUCTION - Decrease in R&D and G&A expenses attributed to disciplined resource allocation after organizational realignment

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$50.30 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.00, about 58.5% above its November 5 closing price of $3.32

Press Release: ID:nBw8h2fYLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581108880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581108880","market":"nz","top_or_hot":-1,"title":"Rocket Pharmaceuticals Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rocket Pharmaceuticals Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Rocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior year</p></li><li><p>R&amp;D and G&amp;A expenses decreased due to disciplined resource allocation</p></li><li><p>Company to resume pivotal Phase 2 trial for Danon disease in 1H 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rocket expects cash resources to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2027</p></li><li><p>Company anticipates dosing additional patients for RP-A501 in H1 2026</p></li><li><p>KRESLADI™ PDUFA date set for March 28, 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>AAV CARDIOVASCULAR FOCUS - Co maintained strategic focus on AAV cardiovascular gene therapy portfolio, resuming pivotal Phase 2 trial for Danon disease</p></li><li><p>EXPENSE REDUCTION - Decrease in R&amp;D and G&amp;A expenses attributed to disciplined resource allocation after organizational realignment</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$50.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.00, about 58.5% above its November 5 closing price of $3.32</p></li></ul><p>Press Release: <span>ID:nBw8h2fYLa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rocket Pharmaceuticals Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRocket Pharmaceuticals Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rocket Pharmaceuticals Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Rocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior year</p></li><li><p>R&amp;D and G&amp;A expenses decreased due to disciplined resource allocation</p></li><li><p>Company to resume pivotal Phase 2 trial for Danon disease in 1H 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rocket expects cash resources to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2027</p></li><li><p>Company anticipates dosing additional patients for RP-A501 in H1 2026</p></li><li><p>KRESLADI™ PDUFA date set for March 28, 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>AAV CARDIOVASCULAR FOCUS - Co maintained strategic focus on AAV cardiovascular gene therapy portfolio, resuming pivotal Phase 2 trial for Danon disease</p></li><li><p>EXPENSE REDUCTION - Decrease in R&amp;D and G&amp;A expenses attributed to disciplined resource allocation after organizational realignment</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$50.30 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.00, about 58.5% above its November 5 closing price of $3.32</p></li></ul><p>Press Release: <span>ID:nBw8h2fYLa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1HV:1","article_id":"2581108880","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581108880","pubTimestamp":1762463353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rocket Pharmaceuticals Q3 net loss narrowsOverviewRocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior yearR&D and G&A expenses decreased due to disciplined resource allocationC","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RCKT":"Rocket Pharmaceuticals, Inc."},"translate_title":"火箭制药第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCKT":0.9},"content_text":"Rocket Pharmaceuticals Q3 net loss narrowsOverviewRocket Pharmaceuticals reports Q3 net loss of $50.3 mln, reduced from prior yearR&D and G&A expenses decreased due to disciplined resource allocationCompany to resume pivotal Phase 2 trial for Danon disease in 1H 2026OutlookRocket expects cash resources to fund operations into Q2 2027Company anticipates dosing additional patients for RP-A501 in H1 2026KRESLADI™ PDUFA date set for March 28, 2026Result DriversAAV CARDIOVASCULAR FOCUS - Co maintained strategic focus on AAV cardiovascular gene therapy portfolio, resuming pivotal Phase 2 trial for Danon diseaseEXPENSE REDUCTION - Decrease in R&D and G&A expenses attributed to disciplined resource allocation after organizational realignmentKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$50.30 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 7 \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $8.00, about 58.5% above its November 5 closing price of $3.32Press Release: ID:nBw8h2fYLaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581108880","isCrawlerRequest":true}